Patent ID: 11891372
Assignee: PFIZER INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 3:
4. A method of treating a hematologic malignancy in a mammal having said hematologic malignancy, comprising administering to the mammal a pharmaceutical composition comprising a therapeutically effective amount of a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, having the structure:, and having: (a) a powder X-ray diffraction pattern comprising peaks at 28 values of: 11.6 and 12.1°2θ±0.2°2θ; and (b) a13C solid state NMR spectrum comprising a resonance (ppm) value of: 148.3 ppm±0.2 ppm, and a pharmaceutically acceptable excipient.